You are here: Welcome » Genentech

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Both sides next revision
genentech [2023/07/12 00:08]
pamela [PHARMAGANDA: A STUDY OF CONFLICTING INTEREST] 		genentech [2023/07/12 00:47] (current)
pamela
Line 1: Line 1:
 ===== Genentech ===== ===== Genentech =====
 {{::genentech_roche.png?400|}} {{::genentech_roche.png?400|}}
 +
  
  
Line 6: Line 7:
 ==== Official History & Timeline 2002 capture ==== ==== Official History & Timeline 2002 capture ====
  
-Genentech was founded in 1976 by venture capitalist [[:Robert A. Swanson]] and biochemist Dr. [[:Herbert W. Boyer]]. In the early 1970s, Boyer and geneticist [[:Stanley Cohen]] pioneered a new scientific field called [[:recombinant DNA]] technology. Excited by the breakthrough, Swanson placed a call to Boyer and requested a meeting. Boyer agreed to give the young entrepreneur 10 minutes of his time. Swanson's enthusiasm for the technology and his faith in its commercial viability was contagious, and the meeting extended from 10 minutes to three hours; by its conclusion, Genentech was born.+Genentech was founded in 1976 by venture capitalist [[:Robert A. Swanson]] and biochemist Dr. [[:Herbert W. Boyer]]. In the early 1970s, Boyer and geneticist [[:Stanley Cohen]] pioneered a new scientific field called [[:recombinant DNA]] technology.  
 + 
 +Excited by the breakthrough, Swanson placed a call to Boyer and requested a meeting. Boyer agreed to give the young entrepreneur 10 minutes of his time. Swanson's enthusiasm for the technology and his faith in its commercial viability was contagious, and the meeting extended from 10 minutes to three hours; by its conclusion, Genentech was born.
  
 Though Swanson and Boyer faced skepticism from both the academic and business communities, they forged ahead with their idea. Within a few short years, they had proved their detractors wrong and invented a whole new industry. Though Swanson and Boyer faced skepticism from both the academic and business communities, they forged ahead with their idea. Within a few short years, they had proved their detractors wrong and invented a whole new industry.
Line 310: Line 313:
 The ethical confrontation surrounding genetic research began in 1971, when Paul Berg of the [[:Stanford University Medical Center]] became the first molecular biologist to create gene-spliced DNA from different species, a feat that, along with his continued work in the field, would win him the Nobel Prize for chemistry in 1980. Berg joined the DNA of two viruses, a common laboratory type known as SV 40 and another called lambda phage. (A phage is a virus that preys on bacteria by injecting its own DNA into them. The new DNA then takes over the biochemical machinery of the host, which gives itself over to making many more copies of the original phage.) The ethical confrontation surrounding genetic research began in 1971, when Paul Berg of the [[:Stanford University Medical Center]] became the first molecular biologist to create gene-spliced DNA from different species, a feat that, along with his continued work in the field, would win him the Nobel Prize for chemistry in 1980. Berg joined the DNA of two viruses, a common laboratory type known as SV 40 and another called lambda phage. (A phage is a virus that preys on bacteria by injecting its own DNA into them. The new DNA then takes over the biochemical machinery of the host, which gives itself over to making many more copies of the original phage.)
  
-Berg wanted to make duplicates of his hybrid DNA for use in subsequent experiments. To do this, he proposed to use his modified lambda phage, which contained the [[:SV 40 genes]], to infect a widely used laboratory bacterium, Escherichia coli. At this point he quickly met criticism from his colleagues, led by Robert Pollack of [[:Cold Spring Harbor Laboratory]].+Berg wanted to make duplicates of his hybrid DNA for use in subsequent experiments. To do this, he proposed to use his modified lambda phage, which contained the [[:SV 40 genes]], to infect a widely used laboratory bacterium, Escherichia coli. At this point he quickly met criticism from his colleagues, led by Robert Pollack of [[:Cold Spring Harbor]] Laboratory.
  
 E. coli lives in the human intestine; the species name coli means “of the colon.” Scientists knew that SV 40 causes tumors in mice and can turn human cells cancerous. What would happen if E. coli cells bearing SV 40 genes escaped from Berg’s lab? Might these altered bugs cause a massive outbreak of colon cancer? Berg could not rule this out, so he abandoned that part of his research. E. coli lives in the human intestine; the species name coli means “of the colon.” Scientists knew that SV 40 causes tumors in mice and can turn human cells cancerous. What would happen if E. coli cells bearing SV 40 genes escaped from Berg’s lab? Might these altered bugs cause a massive outbreak of colon cancer? Berg could not rule this out, so he abandoned that part of his research.
Line 417: Line 420:
  
 T. A. Heppenheimer is a frequent contributor to Invention & Technology.((https://web.archive.org/web/20081203133822/http://www.americanheritage.com/articles/magazine/it/2001/4/2001_4_8.shtml)) T. A. Heppenheimer is a frequent contributor to Invention & Technology.((https://web.archive.org/web/20081203133822/http://www.americanheritage.com/articles/magazine/it/2001/4/2001_4_8.shtml))
 +
 +==== FREE Zone Foreign Labs for Banned Research ====
 +
 +The Italian Business Council Dubai hosts a business luncheon with [[:DuBiotech Free Zone]] Executive Director
 +
 +United Arab Emirates: Wednesday, March 24 - 2010 at 12:04
 +
 +The Italian Business Council Dubai (IBCD) hosted a business luncheon with special guest Dr. Marco Baccanti, Executive Director of **Dubai Biotechnology and Research Park** (DuBiotech) - the major life sciences hub in the Middle East and a member of Tecom Investments - at the Shangri La Hotel.
 +
 +Dr. Ottavia Molinari, President of the Italian Business Council Dubai after welcoming the numerous guests introduced Dr. Marco Baccanti, Dubiotech Free Zone Executive Director who delivered a speech with special topic `**Benefits of the free zone for the Life Sciences Industry in Dubai**`.
 +
 +Dr. Marco Baccanti, said; "Launched in 2005, the Dubai Biotechnology and Research Park, has the mission to create the biggest [[:life sciences]] cluster in the Middle East, adopting a sustainable strategy. Its business model is based on providing the best environment for major players in the life sciences industry and research through leveraging the benefits of its location in Dubai, offering free zone benefits and creating world class infrastructure."
 +
 +Dr. Baccanti explained that the **free zone currently hosts already 65 major pharmaceutical firms** including [[:Pfizer]], [[:Genzyme]], [[:Merck]] -Serono and Amgen as well as companies specialized in biomedical and scientific devices, biotechnology, cosmesis, and enzymes.
 +
 +He added, "DuBiotech offers flexible laboratory space as one of the key components of the sprawling business park. In addition to hosting a range of assets varying from offices to warehouses and land for manufacturing, the 22 million sq. ft. biotechnology cluster enjoys a strategic location with world-class infrastructure. **A number of free zone-associated incentives such as full ownership, tax-free profit repatriation and business friendly environment** that DuBiotech offers makes the cluster an ideal destination for life sciences companies seeking to address the fast growing regional markets."
 +
 +Copyrights © 2010 IBCD - All Rights Reserved Privacy Policy | Legal Notice
 +(no archive capture original URL is gone http://www.ibcdubai.ae/press_details_view.asp?id=JNMMIMQ8)
 +
 +==== Funding Universe DuPuy Pharma Lineage ====
 +
 +1992: DePuy forms alliance with Genentech, Inc
 +
 +Key Dates:
 +
 +1895- Revra DePuy founds DePuy Manufacturing in Warsaw, Indiana.
 +
 +1921- Revra DePuy dies; his wife Winifred takes control of the company.
 +
 +1949- Winifred dies, and passes control of company to her second husband, Herschel Leiter; Herschel Leiter marries Amrette Webb Ailes.
 +
 +1950- Leiter dies.
 +
 +1951- Amrette Leiter marries Harry Hoopes; the couple run DePuy jointly.
 +
 +1965- A group of investors, led by Bill Weaver, purchases DePuy from the Hoopeses.
 +
 +1968- DePuy is acquired by Bio-Dynamics; DePuy enters hip replacement sector; DePuy purchases Kellogg Industries.
 +
 +1974- DePuy is acquired by Boehringer Mannheim Companies (owned by Corange Ltd.).
 +
 +1987- DePuy forms a partnership with E.I. [[:duPont]] de Niemours and Co.
 +
 +1990- Boehringer Mannheim purchases Charles F. Thackray Ltd.
 +
 +1992- DePuy forms alliance with [[:Genentech]], Inc.; DePuy acquires the Rotek Company.
 +
 +1993- DePuy enters into a joint venture with Biedermann Motech dubbed DePuy Motech.
 +
 +1994- Corange purchases ACE Medical Products and forms new company, DePuy ACE Medical Co.
 +
 +1996- DePuy acquires Landanger-Camus; Corange announces an IPO for DePuy.
 +
 +1998- Roche Holding Ltd. purchases Corange in a transaction that includes DePuy; DePuy acquires AcroMed Corp., thereby becoming the world's second largest spinal implant company; [[:Johnson & Johnson]] purchases DePuy from Roche.((https://web.archive.org/web/20060505075732/http://www.fundinguniverse.com/company-histories/DePuy-Inc-Company-History.html))
 +
 +
 +
 +
 +
Back to top